Colossal Biosciences in Talks to Raise Capital at $20B–$30B Valuation
De-extinction startup Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion. This would represent a doubling or tripling of the company's previous valuation. The news comes according to a report from TechCrunch.
Colossal Biosciences, the ambitious de-extinction startup known for its efforts to bring back species like the woolly mammoth and the Tasmanian tiger, is reportedly in talks to raise a significant new round of funding. According to TechCrunch, the company is targeting a valuation of between $20 billion and $30 billion in its latest capital-raising discussions.
This new valuation would represent a dramatic leap from the company's previous funding rounds, where it was valued at approximately $10 billion. A successful raise at the reported figures would effectively double or triple that earlier valuation, underscoring the intense investor appetite for cutting-edge biotechnology ventures.
Colossal Biosciences has made headlines repeatedly for its bold scientific ambitions, combining genetic engineering, synthetic biology, and conservation efforts. The company has attracted high-profile backers and garnered widespread media attention since its founding, helping it grow into one of the most recognizable names in the biotech startup space.
If the fundraising talks prove successful, Colossal would cement its status as one of the most valuable private biotech companies in the world. The outcome of these negotiations could also signal broader trends in how investors view the intersection of biology, technology, and environmental restoration.